ArticleCureus2026
A Diagnostic Challenge in the Emergency Department: Acute Intermittent Porphyria Unmasked After Cabergoline Exposure.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute intermittent porphyria is a rare metabolic disorder that often presents with recurrent abdominal pain and nonspecific gastrointestinal symptoms, frequently leading to diagnostic delays in emergency settings. We report the case of a 24-year-old woman with glucose-6-phosphate dehydrogenase deficiency diagnosed at birth and pituitary prolactinoma treated with cabergoline 0.5 mg twice weekly, initiated one month before symptom onset, who presented with recurrent severe epigastric pain and vomiting over the course of one year. Repeated laboratory investigations and contrast-enhanced computed tomography of the abdomen and pelvis were unremarkable, and symptoms required opioid analgesia during multiple emergency department visits. A subsequent metabolic evaluation revealed elevated urinary porphyrin precursors, confirming acute intermittent porphyria. Following diagnosis, the cabergoline dose was reduced to 0.25 mg twice weekly with close monitoring of prolactin levels. During two years of follow-up, she experienced two recurrent attacks that were successfully managed with 2 L of 10% dextrose administered intravenously over three hours, along with opioid analgesia. This case highlights the importance of considering acute intermittent porphyria in patients with recurrent unexplained abdominal pain and emphasizes the possible role of medication-related and endocrine factors as indirect triggers, particularly in resource-limited settings where definitive therapy may not be available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.